IDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB)

BackgroundPotent antivirals can reduce HCC incidence in CHB. TDF and TAF are first-line treatments, and in Phase 3 studies through 3 years, TAF has shown antiviral efficacy similar to TDF, higher rates of ALT normalization, and no resistance. We evaluated HCC incidence in patients participating in t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2020-11, Vol.69 (Suppl 2), p.A75-A76
Hauptverfasser:	Yuen Chan, Henry Lik, Lim, Young-Suk, Seto, Wai Kay, Ning, Qin, Agarwal, Kosh, Janssen, Harry LA, Pan, Calvin O, Chuang, Wan Long, Izumi, Namiki, Fung, Scott, Brunetto, Maurizia, Flaherty, John, Mo, Shuyuan, Cheng, Cong, Lin, Lanjia, Gaggar, Anuj, Subramanian, Mani, Marcellin, Patrick, Gane, Edward, Hou, Jinlin, Buti, Maria
Format:	Artikel
Sprache:	eng
Schlagworte:	Ablation Algorithms Antiretroviral drugs Antiviral agents Biomarkers Cirrhosis Clinical trials Creatinine Decision making Deoxyribonucleic acid Disease DNA Fasting Hepatitis Hepatitis B Hepatitis B e antigen Hepatocellular carcinoma HIV Hospitals Human immunodeficiency virus Lipids Liver cancer Liver cirrhosis Machine learning Medicine Proteins Tenofovir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!